Home > Boards > US Listed > Biotechs >

Geron Corp. (GERN)

Add GERN Price Alert      Hide Sticky   Hide Intro
Moderator: subslover
Search This Board: 
Last Post: 1/13/2018 11:52:31 PM - Followers: 189 - Board type: Free - Posts Today: 0

 Geron Corp (GERN)




Company Information:
Geron Corporation
Constitution Drive
Menlo Park, CA 94025 USA
Tel: 650-473-7700
Fax: 650-473-7750



CIK:  0000886744


Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials in different cancers.

Incorporated in the state of Delaware in 1990, Geron has been in business since 1992. Our headquarters and main facilities are located in Menlo Park, California. Geron Bio-Med Limited is our wholly-owned subsidiary located in Edinburgh, Scotland. TA Therapeutics, Limited is our majority-owned subsidiary located in Hong Kong.


Executive Management:




Geron Bio-Med Ltd

TA Therapeutics


Recent News:





Transfer Agent:
Computershare Trust Company, N.A.
250 Royall Street
Canton, MA 02021
Tel: 1-800-962-4284
Fax: 303-262-0700


Investor Relations:

Tel: 650-473-7765



Geron Clinical Trials








Acute Myelogenous Leukemia is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.

Alzheimer's Disease: Alzheimer's disease is a progressive, fatal, degenerative disorder that attacks the neurons in the brain, resulting in loss of memory, cognitive function such as reasoning and language, and behavioral changes. The disease starts with the loss of neural connections, called synapses, in the hippocampus, affecting memory, and progresses to the cortex affecting language and thought.

Antiplatelet: Medication, including aspirin and newer agents used to prevent clumping together of platelets, one of the first things to occur in artery clotting. Platelet clumping is a risk factor for stroke.

Autologous refers to cells, tissues or even proteins that are reimplanted in the same individual as they come from. Bone marrow, skin biopsy, cartilage, and bone can be used as autografts.

A Chromosome is a part of a cell in an animal or plant. It contains genes which determine what characteristics the animal or plant will have.

Cytogenetics is a branch of genetics that is concerned with the study of the structure and function of the cell, especially the chromosomes.

Dendritic is a short branch at the end of a nerve cell, which receives signals from other cells.

Ecchymosis is the escape of blood from ruptured blood vessels into the surrounding tissue to form a purple or black-and-blue spot on the skin.

The Hippocampus is a major component of the brains of humans and other mammals. It belongs to the limbic system and plays important roles in long-term memory and spatial navigation.

Idiopathic is an adjective used primarily in medicine meaning arising spontaneously or from an obscure or unknown cause.

Immunotherapy is a medical term defined as "Treatment of disease by inducing, enhancing, or suppressing an immune response"

Interim is used to describe something that is intended to be used until something permanent is done or established.

Intracranial: Of or pertaining to the brain or inside of the head. Within the cranium.

Leukapheresis is a laboratory procedure in which white blood cells are separated from a sample of blood.

The Limbic system (or Paleomammalian brain) is a set of brain structures including the hippocampus, amygdala, anterior thalamic nuclei, and limbic cortex, which support a variety of functions including emotion, behavior, long term memory, and olfaction.[1] The term "limbic" comes from Latin limbus, loosely translating as "border" or "belt".

Lysosome: A sac-like compartment inside a cell that has enzymes that can break down cellular
components that need to be destroyed.

Macrophages: A large cell that acts as a scavenger, helping the immune system to destroy foreign agents.

Remission If someone who has had a serious disease such as cancer is in remission or if the disease is in remission, the disease has been controlled so that they are not as ill as they were.

T cells or T lymphocytes belong to a group of white blood cells known as lymphocytes, and play a central role in cell-mediated immunity. They can be distinguished from other lymphocyte types, such as B cells and natural killer cells by the presence of a special receptor on their cell surface called T cell receptors (TCR).

Thrombocytopenic purpura A systemic illness characterized by extensive ecchymoses and hemorrhages from mucous membranes and very low platelet counts; resulting from platelet destruction by macrophages due to an antiplatelet factor; childhood cases are usually brief and rarely present with intracranial hemorrhages, but adult cases are often recurrent and have a higher incidence of grave bleeding, especially intracranial.
Transfection of animal cells typically involves opening transient pores or "holes" in the cell membrane, to allow the uptake of material. Genetic material (such as supercoiled plasmid DNA or siRNA constructs), or even proteins such as antibodies, may be transfected.

NOTE: Definitions found with Google. All comments or suggestions are welcome.

_____________________________________________________________________________________________________________________________________________________________________________ ARE TELOMERES AND TELOMERASE ?

Geron Corporation is a biotechnology company founded by Dr. Michael D. West based in Menlo Park, California. The company was incorporated in 1990 and began doing business in 1992. Geron Corporation focuses on creating drugs based on telomere and stem cell research[3].

Geron is traded on the NASDAQ under the symbol GERN. The current chief executive officer is Dr. Thomas B. Okarma, M.D., Ph.D. It was included in the SCCC Index, a 15 stock index of companies important "to the field of stem cell, cloning, and cell transplantation research and medicine" when that index was created in 2003 and as of July 2006 comprises 18.42% of the index[4].

The company specializes in developing and commercialization of products in three specific areas: 1) therapeutic products for cancer that inhibit telomerase; 2) pharmaceuticals that activate telomerase in tissues impacted by cell aging, injury or degenerative diseases; and 3) cell-based therapies derived from human embryonic stem cells for treatment of various chronic diseases[5].

Currently, Geron Corporation has two anti-cancer products in human clinical trials. The first, called GRN163L, is a drug that targets telomerase and has been shown to be effective in treating various cancers in animals[6]. In studies conducted at Johns Hopkins University GRN163L was active against both CD138+ and CD138neg cancer stem cells and eliminated the colony forming potential of both by five weeks. Similarly, GRN163L inhibited the in vitro clonogenic growth of CD138neg Multiple Myeloma Cancer Stem Cells isolated from the bone marrow aspirates of patients with Multiple Myeloma. Geron has started human clinical trials and is testing GRN163L in patients with lymphocytic leukemia[7]. Presently Geron is recruiting patients for six clinical trials using GRN163L, including lung cancer[8], chronic lymphocytic leukemia[9], solid tumors[10].Also in trials at Duke University is GRNVAC1, a telomerase vaccine being used on patients with prostate cancer. With the vaccine, Geron plans to inject telomerase into the patient with metastatic prostate cancer to induce the body to produce a more aggressive immune response to the cancer. This vaccine has also produced significant initial results. Geron's progress with these telomerase drugs has been significant enough to have elicited a significant monetary investment in 2005 from Merck[11].

In addition to testing drug candidates that exploit cancer cell's dependence on telomerase, Geron is researching the possible applications of activating the enzyme in normal cells to delay cellular senescence. The company is in the early stages of developing a telomerase based treatment for HIV called TAT0002 from astragalus which is actually the saponin cycloastragenol in Astragalus[12]. Geron has granted a license to to sell TA-65, the telomerase activator agent derived from the Chinese astragalus plant.

On January 23, 2009, Geron received FDA approval to begin Phase I testing of GRNOPC1 in humans [13]. GRNOPC1 is an embryonic stem cell based drug that is designed to treat spinal cord injuries. Animal tests have shown significant restoration of mobility in animals with spinal injuries that were treated with this drug [14]. Geron also has several other embryonic stem cell treatments that are still in the preclinical phase, including GRNCM1, a treatment for heart disease, and GRNIC1, a treatment for diabetes. In tests with diabetic mice, 80% of the mice given GRNIC1 were still alive in 50 days while the entire control group, which was given no treatment, perished[15].

Since it was organized in 1990 Geron has been granted over 260 patents

Geron Corporation's patents in stem cell technology

Geron Corporation initially held exclusive rights to three cell types derived from embryonic stem cells, as the result of paying for the research originally conducted by Dr. James Thomson at the University of Wisconsin-Madison.[17] The patents on the other three cell types are owned by the Wisconsin Alumni Research Foundation (WARF). WARF and Geron did not charge academics to study human stem cells but did charge commercial users. In 2001 WARF came under public pressure to widen access to human stem-cell technology, and they launched legal action against Geron Corporation to recover some of the previously sold rights. The two sides agreed that Geron would keep the rights to only three cell types.[18]

In October 2006, a legal challenge was mounted to overturn these patents by The Foundation for Taxpayer and Consumer Rights and the non-profit patent-watchdog Public Patent Foundation.[19] They contended that two of the patents granted to WARF are invalid because they cover a technique published in 1992 for which a patent had already been granted to an Australian researcher. Another part of the challenge came from the molecular biologist Jeanne Loring who stated that University of Wisconsin-Madison stem cell pioneer James Thomson's techniques (currently patents held by WARF) are rendered obvious by a 1990 paper and two textbooks.[20] The outcome of this legal challenge was particularly relevant to the Geron Corporation as it can only license patents that are upheld.[21] The patents were ultimately upheld when the reexamination concluded in 2008.[22]

As an interim measure, on January 23, 2007 WARF relaxed the stem cell patents, allowing industry-sponsored research at academic and non-profit institutions without a license.[23] WARF will allow easier and simpler cost free cell transfers among researchers and would not require a license or agreement from California's taxpayer-funded stem cell research program.[24]


  1. ^ Geron press release January 23 2009: Geron Receives FDA Clearance to Begin World's First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
  2. ^ GERN: Profile for GERON CORP - Yahoo! Finance
  3. ^ The Bulletin - Philadelphia's Family Newspaper - Deja Vu All Over Again With Stem Cells
  4. ^ Stem Cell Stocks : companies, profiles and links
  5. ^ GERON
  6. ^ Geron Announces Data on the Effects of Its Cancer Drug, GRN163L, on Multiple Myeloma at the American Society of Hematology Annual Meeting
  7. ^ Safety and Dose Study of GRN163L Administered Weekly to Treat Patients With Chronic Lymphocytic Leukemia (CLL) - Full Text View -
  8. ^ [GRN163L]
  9. ^ Safety and Dose Study of GRN163L Administered Weekly to Treat Patients With Chronic Lymphocytic Leukemia (CLL)
  10. ^ Safety and Dose Study of GRN163L Administered Weekly to Treat Patients With Solid Tumor Malignancies
  11. ^ Geron plans stock offering, Merck buying $18M in shares - Silicon Valley / San Jose Business Journal:
  12. ^ TAT2 (cycloastragenol, CAS Registry no. 84605-18-5)
  13. ^ Despite Bush Veto, Stem Cell Research Abounds -
  14. ^ Keirstead HS, Nistor G, Bernal G, et al (May 2005). "Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury". J. Neurosci. 25 (19): 4694-705. doi:10.1523/JNEUROSCI.0311-05.2005. PMID 15888645. 
  15. ^ News: Geron Presents New Data That Document Progress in Development of Therapeutic Products from Human Embryonic Stem Cells. Genetic Engineering & Biotechnology News - Biotechnology from Bench to Business
  16. ^ Geron - Patents
  17. ^ The Badger Herald - WARF, Geron reach settlement
  18. ^ Center for Genetics and Society : How a University's Patents May Limit Stem-Cell Research
  19. ^ _Science_, 2006
  20. ^ Nature Reports Stem Cells 8 November 2007
  21. ^ Center for Genetics and Society : Stem Cell Patents Come Under Fire
  22. ^ WARF press release
  23. ^ > News > Business > Biotechnology - Stem cell scientists shout out hallelujah
  24. ^
  25. ^ Geron's Cloning Quandary -
  26. ^ BW Online | June 2, 2003 | Online Extra: Thomas Okarma: Don't Ban Stem-Cell Research
  27. ^ H.R. 1644, Human Cloning Prohibition Act of 2001, and H.R.____, Cloning Prohibition Act of 2001



Link to stockshark77's 1743 post regarding Geron's work with telomerase

Link to Postman's 1440 post regarding Geron's possible price per share

Link to KarinCA's 1542 post regarding Corning and Geron collaboration.

Link to Postman's 1442 post regarding GE Healthcare and Geron collaboration

Link to krays' 1545 post with CBS video regarding Geron and spinal cord injury.

Link to Postman's 1583 post with a list of clinical trials

Link to Paula's 1623 post with information regarding embryonic stem cell research


Opinions expressed on this board are just that. Opinions. We are not licensed brokers. Trading strategies discussed on this board are often high risk and not suitable for everyone. If you are losing money in the market, you may wish to seek the advice of a licensed securities professional.

No one is responsible for your gains or losses in the market except for you. If you follow stocks, strategies discussed on this board, you may lose all your money. Please weigh the strategies discussed here carefully against what you are willing to risk.

Please do your own due diligence before buying or selling any security in the open market, there are no guarantees.


Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GERN News: Current Report Filing (8-k) 01/08/2018 07:49:08 AM
GERN News: Statement of Changes in Beneficial Ownership (4) 01/02/2018 06:29:01 PM
GERN News: Statement of Changes in Beneficial Ownership (4) 01/02/2018 06:22:42 PM
GERN News: Statement of Changes in Beneficial Ownership (4) 01/02/2018 06:14:47 PM
GERN News: Current Report Filing (8-k) 12/12/2017 07:42:32 AM
#3976  Sticky Note Geron: S-L-O-W Progress subslover 08/02/17 01:07:05 PM
#3997   Sorry it took me so long to reply... Liquid_Bull 01/13/18 11:52:30 PM
#3996   I love your style! Not too many investors subslover 01/12/18 01:21:10 PM
#3995   been long GERN for about 10 yrs now... Shel_SWFL 01/12/18 12:37:35 PM
#3994   Haven't seen you in years! Here is a subslover 01/12/18 11:59:40 AM
#3993   Seems likely to pop soon... anybody else have Liquid_Bull 01/11/18 11:10:48 AM
#3992   Geron Corporation's (GERN) Post ASH Investor & Analyst subslover 12/20/17 02:15:33 PM
#3991   Geron (GERN) Post ASH Investor & Analyst Event subslover 12/19/17 02:41:30 PM
#3989   Geron's Upcoming Conference Call May Surprise With Data subslover 12/19/17 08:56:07 AM
#3988   12/7: Exponential growth potential. GERN listed as one Saskey 12/07/17 09:15:07 AM
#3987   UPDATE subslover 12/06/17 01:21:38 PM
#3986   Geron Short Interest Is Dropping Steadily subslover 11/17/17 07:29:44 PM
#3985   Geron Corporation's (GERN) CEO Dr. John Scarlett on subslover 11/01/17 11:45:40 PM
#3984   * * $GERN Video Chart 10-31-17 * * ClayTrader 10/31/17 05:10:38 PM
#3983   10/31: Geron Announces Fast Track Designation Granted to Saskey 10/31/17 10:30:23 AM
#3982   Geron up 13% premarket on U.S. Fast Track subslover 10/31/17 08:48:57 AM
#3981   Geron (GERN) Presents At Cantor Fitzgerald Global Healthcare subslover 09/27/17 05:18:46 PM
#3980   Geron (GERN) imetelstat can potentially bring about a subslover 09/20/17 01:01:10 PM
#3978   Geron's Imetelstat: Obstacles To Success subslover 08/10/17 07:21:40 PM
#3977   Geron Corporation Reports Second Quarter 2017 Financial Results subslover 08/10/17 08:27:32 AM
#3976   Geron: S-L-O-W Progress subslover 08/02/17 01:07:05 PM
#3975   How could you have known!Nobody knew.These yellow belly subslover 08/01/17 10:28:53 AM
#3974   Didn't get a chance to listen to the vnmonk 08/01/17 10:19:46 AM
#3973   NEVER ENDING DRAGGED OUT UNTIL LATE 2018 subslover 08/01/17 10:11:22 AM
#3972   Thanks for sharing subslover 07/30/17 12:10:45 AM
#3971   Here's the court doc on the 7/21 hearing vnmonk 07/29/17 07:39:04 PM
#3970   A Look At Geron's Potential Myelofibrosis Competition subslover 07/05/17 11:38:39 PM
#3969   A Look At The Competition Geron Could Face subslover 06/29/17 06:25:55 PM
#3968   Geron: Wishing And Hoping subslover 06/27/17 11:48:48 PM
#3967   $GERN $3.15 new 52 week high! subslover 05/16/17 10:13:56 AM
#3966   Were back to $3.00 subslover 05/15/17 10:30:28 AM
#3965   Wall Street liked the voting at the stockholders subslover 05/12/17 10:43:26 AM
#3964   Earnings out subslover 05/10/17 12:53:13 AM
#3963   Analyst update subslover 05/10/17 12:47:47 AM
#3962   Very interesting analytical update subslover 04/17/17 02:12:56 PM
#3961   Geron settling class-action securities suit for $6.25M subslover 04/11/17 01:19:38 AM
#3960   * * $GERN Video Chart 04-10-17 * * ClayTrader 04/10/17 05:10:58 PM
#3959   IF ever-- how much do you think JJ Srudyk 04/10/17 05:08:41 PM
#3958   Oops, Geron ! redskins020 04/10/17 01:25:07 PM
#3957   Seems to me J & J wouldn't want redskins020 04/10/17 01:23:47 PM
#3956   It was not a portend of bad news, ilpapa 04/10/17 11:02:00 AM
#3955   Thanks...none issue to me...I don't follow Adam Feuerstein 654321 04/10/17 09:23:26 AM
#3954   "Geron expects the longer-term data from the trial, davidsson10 04/10/17 08:52:32 AM
#3953   AF again huh? Surprised he ain't been martind18 04/10/17 08:38:56 AM
#3952   I might be missing it but I'm not 654321 04/10/17 08:34:42 AM
#3951   *Adam Feuerstein Tweets: $JNJ reluctance to commit to davidsson10 04/10/17 08:10:50 AM
#3950   Price...$2.75 654321 04/10/17 07:50:13 AM
#3949   Two more Form T trades this morning...150 & 654321 04/10/17 07:11:46 AM
#3948   It looks like they're trying to get the 654321 04/10/17 06:56:43 AM
#3947   News... 654321 04/10/17 06:51:52 AM
#3946   As for your question...I don't know. My 654321 04/10/17 06:49:27 AM